Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.38 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7888589 | 0.91 | HRH3 (0.43) | HRH3HTR3AACVR1KDM4ENPC1 | |
| SCHEMBL421611 | 0.89 | HRH3 (0.45) | HRH3HRH4HTR3AKDM4ENPC1 | |
| SCHEMBL10176659 | 0.80 | ALDH1A1 (0.42) | HTR3AKDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL422628 | 0.79 | MAP4K1 (0.37) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL417697 | 0.79 | IRAK4 (0.41) | HRH3HRH4ACVR1GRM2 | |
| SCHEMBL7886302 | 0.79 | MAPT (0.48) | HRH3HTR3AKDM4ENPC1ALDH1A1 | |
| SCHEMBL422484 | 0.78 | KDM4E (0.42) | HRH3HTR3AKDM4ENPC1ALDH1A1 | |
| SCHEMBL419627 | 0.78 | CHRNA7 (0.40) | F10 | |
| SCHEMBL10176614 | 0.77 | SMN1; SMN2 (0.43) | HTR3AKDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL422446 | 0.76 | MAPT (0.52) | HRH3KDM4ENPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885HRH4 2/4885HTR3A 49/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885HRH4 2/4885HTR3A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.